Stemcyte®, Inc. surpasses 300th cord blood unit shipped for transplant
May 4, 2006 StemCyte has now provided cord blood units to over 130 transplant centers worldwide across 6 continents, and the number of units released for transplantation is rapidly increasing.
ARCADIA, Calif. (May 4, 2006)-StemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently shipped its 300th cord blood stem cell unit for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 95 transplant centers worldwide across 5 continents, with the number of units released for transplantation increasing rapidly. StemCyte's units have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.

'This is an especially exciting time for the cord blood stem cell industry as now more and more transplant centers are using cord blood for both children and adult transplantations,' says StemCyte's CEO Ken Giacin. 'We are also seeing more transplants for non-malignant diseases such as thalassemia, with several patients receiving double cord blood transplants, an exciting and cutting-edge protocol. StemCyte expects to grow rapidly in terms of the number of transplant centers that we serve and the number of patients whose lives are saved by our units.'

'We are very pleased with the growing vote of confidence that is being extended to StemCyte by transplant physicians around the world,' said Lawrence D. Petz, M.D., Chief Medical Officer, StemCyte International Cord Blood Center, and Emeritus Professor of Pathology and Laboratory Medicine, UCLA Medical Center. 'Our consistently excellent one-year patient survival data continue to point to both the increasing level of transplant physician care as well as to the high degree of efficacy of our cord blood units.'

To find out more visit StemCyte online at www.stemcyte.com.